Response to Comments: MolDX: Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer

This document is a response to comments for the MolDX policy on Inivata InVisionFirst liquid biopsy for lung cancer and contains only administrative metadata (comment period: 10/04/2018–12/14/2018; notice period: 04/18/2019–06/02/2019). It does not include clinical coverage criteria, limitations, documentation requirements, or frequency limits. Refer to the final LCD DL37897 (effective 06/03/2019) for the complete coverage policy.

"No clinical indications or coverage criteria are specified in this response-to-comments document; refer to the final LCD DL37897 (effective 06/03/2019) for covered indications."

Sign up to see full coverage criteria, indications, and limitations.